

PCL Department Publications - 1997

"A, B"

Cortez M, Hwang P, **Burnham WM**: Infantile spasms: seasonal onset differences and zeitgebers. *Pediatr Neurol.* 16: 220-224 (1997).

Francis J, Jugloff DGM, Mingo NS, Wallace MC, Jones OT, **Burnham WM**, Eubanks JH: Kainic acid induced generalized seizures alter the regional hippocampal expression of the rat Kv4.2 potassium channel gene. *Neurosci Lett.* 232: 91-94 (1997).

Gombos Z, Mendonca A, Racine RJ, Cottrell GA, **Burnham WM**: Long-term enhancement of entorhinal-dentate evoked potentials following "modified" ECS in the rat. *Brain Res.* 766: 168-172 (1997).

Mingo NS, Cottrell G, Zhang L, Wallace MC, **Burnham WM**, Eubanks JH: Kainic acid-induced generalized seizures alter the regional hippocampal expression of the rat m1 and m3 muscarinic acetylcholine receptor genes. *Epilepsy Res.* 29: 71-79 (1997).

"C"

Campisi P, **Carmichael FJL**, Crawford M, Orrego H, Khanna, J.M: Role of adenosine in the ethanol induced potentiation of general anesthetics. *Eur J Pharmacol.* 325: 165-172 (1997).

"D"

Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, **DaSilva J**, Houle S: [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. *Neurology* 48: 1578-1583 (1997).

Houle S, Wilson AA, Inaba T, Fischer N, **DaSilva JN**: Imaging the 5-HT1A receptors with positron emission tomography: initial humans studies with [11C]CPC-222. *Nucl Med Comm.* 18: 1130-1134 (1997).

Kapur S, Zipursky RB, Jones C, Wilson AA, **DaSilva JN**, Houle S: Cyproheptadine: a potent in vivo serotonin antagonist. *Am J Psychiatry* 154: 884 (1997).

Kapur S, Jones C, **DaSilva JN**, Wilson AA, Houle S: Reliability of a simple non-invasive method for the evaluation of 5-HT2 receptors using [18F]-setoperone PET imaging. *Nucl Med Comm.* 18: 395-399 (1997).

Baker B, **Dorian P**, Sandor P, Shapiro C, Schell C, Mitchell J, Irvine MJ: Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. *J Clin Psychopharmacol.* 17: 15-21 (1997).

Dorian P: Etiologies of electric storm. *Arch Maladies Coeur Vaisseaux* 1: 27-31 (1997).

Dorian P, Cass D: An overview of the management of electrical storm. *Can J Cardiology* 13A: 13A-17A (1997).

Dorian P, Newman D: Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements. *Cardiovascular Res.* 33: 485-494 (1997).

Freeman MR, Newman D, **Dorian P**, Barr A, Langer A: Relation of direct assessment of cardiac autonomic function with metaiodobenzylguanidine imaging to heart rate variability in diabetes mellitus. *Am J Cardiol.* 80: 247-250 (1997).

Lee SD, Newman D, Ham M, **Dorian P**: Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence. *J Am Coll Cardiology* 29: 100-105 (1997).

Mazer CD, Greene MB, Misale PS, Newman D, **Dorian P**: Transcutaneous T wave shock: a universal method for ventricular fibrillation induction. *Pacing Clin Electrophysiology* 20: 2930-2935 (1997).

Nanthakumar K, Newman D, Paquette M, Greene M, Rakovich G, **Dorian P**: Circadian variation of sustained ventricular tachycardia in patients subject to standard adrenergic blockade. *Amer Heart J.* 134: 752-757 (1997).

Newman D, Barr A, Greene M, Martin D, Ham M, Thorne S, **Dorian P**: A population-based method for the estimation of defibrillation energy requirements in humans. Assessment of time-dependent effects with a transvenous defibrillation system. *Circulation* 96: 267-273 (1997).

"E"

Endrenyi L, Gao M, Hao Y: Exploratory and population pharmacodynamic analysis of pilot dose-response data in the bioequivalence testing of topical corticosteroid preparations. *Drug Information J.* 31: 1215-1226 (1997).

Endrenyi L, Tothfalusi L: Is C_{max}/AUC useful for bioequivalence testing? Response. *J Pharm Sci.* 86: 1505-1506 (1997).

Endrenyi L, Tothfalusi L: Secondary metrics for the assessment of bioequivalence. *J Pharm Sci.* 86: 401-402 (1997).

Endrenyi L, Tothfalusi L: Truncated AUC evaluates effectively the bioequivalence of drugs with long half-lives. *Int J Clin Pharmacol Ther.* 35, 142-150 (1997).

Endrenyi L: Some issues for the consideration of individual bioequivalence. *J Biopharm Stat.* 7:35-39 (1997).

Zha J, **Endrenyi L:** Variation of the peak concentration following single and repeated drug administrations in investigations of bioavailability and bioequivalence. *J Biopharm Stat.* 7: 191-204 (1997).

"F"

Le Tran Y, **Forster C:** Chloroethylclonidine and alpha-adrenoceptor agonist interaction in blood vessels following heart failure. *Eur J Pharmacol.* 336: 177-185 (1997).

Le Tran Y, Fung A, **Forster C:** Role of gender and vascular endothelium in rat aorta response to 17beta-estradiol. *Can J Physiol Pharmacol.* 75: 1393-1397 (1997).

Le Tran Y, **Forster C:** Angiotensin (1-7) and the rat aorta: Modulation by the endothelium. *J Cardiovasc Pharmacol.* 30: 676-682 (1997).

"G"

Jin H, Zastawny R, **George SR,** O'Dowd BF: Elimination of palmitoylation sites in the human D1 dopamine receptor by site-directed mutagenesis does not affect receptor-G protein coupling. *Eur J Pharmacol.* 324: 109-116 (1997).

Jung BP, Nguyen T, Kolakowski LF jr., Lynch KR, Heng HQ, **George SR,** O'Dowd BF: Discovery of a novel human G protein-coupled receptor gene (GPR25) located on chromosome. *Biochem Biophys Res Comm.* 230: 69-72 (1997).

Ng GYK, Varghese G, Chung HC, Trogadis J, Seeman P, O'Dowd BF, **George SR:** Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells. *Endocrinology* 138: 4199-4205 (1997).

Ng GYK, **George SR,** O'Dowd BF: Studies on Dopamine Receptors and Role in Drug Addiction. In: *Handbook of Psychiatric Genetics.* CRC Press, Inc, pp. 89-105 (1997).

O'Dowd BF, Nguyen T, Lynch K, Kolakowski F, Thompson M, Cheng R, Marchese A, Ng G, Heng HHQ, **George SR:** A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain. *FEBS Letters* 394: 325-329 (1997).

O'Dowd BF, Nguyen T, Jung B, Marchese A, Cheng R, Heng HHQ, Kolakowski LF, Lynch K, **George SR:** Cloning and chromosomal mapping of four novel human G protein-coupled receptor genes. *Gene* 187: 75-81 (1997).

Pak Y, O'Dowd BF, **George SR**: Agonist-induced desensitization of the mu opioid receptor is determined by 394Thr preceded by acidic amino acids in the COOH terminal tail. *J Biol Chem.* 272: 24961-24965 (1997).

Sawzdargo M, **George SR**, Nguyen T, Xu S, Kolakowski LF, O'Dowd BF: A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to the CD22 gene on chromosome 19q13.1. *Biochem Biophys Res Comm.* 239: 543-547 (1997).

Zastawny RL, **George SR**, Bouvier M, O'Dowd BF: Structure of the Adrenergic and Related Receptors. In: *Encyclopedia of Human Biology*, Second Edition, Vol. 1, Academic Press. pp145-156 (1997).

Goldenberg GJ, Moore MJ: Nitrogen mustards. In: Teicher BA, ed. *Cancer Therapeutics: Experimental and Clinical Agents*. Humana Press, Totowa, New Jersey, pp 3-23 (1997).

McPherson JP, Deffie AM, Jones NR, Brown GA, Deuchars KL, **Goldenberg GJ**: Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA Topoisomerase II. *Anticancer Res.* 17: 4243-4252 (1997).

Ahmad N, **Grad HA**, Haas DA, Aronson KA, Jokovic A, and Locker D: The efficacy of non-opioid analgesics for post-operative dental pain: a meta-analysis. *Anesthesia Progress* 44: 119-127 (1997).

Grad HA (1997): Antibiotics in endodontics- therapeutic considerations. *Alpha Omegan.* 90: 64-71 (1997).

Walker SE, Walshaw PR, **Grad HA**: Imipenem stability and staining of teeth. *Can Soc Hosp Pharm.* 50: 61-67 (1997).

Walker SE, **Grad HA**, Haas DA, Mayer A: Stability of parenteral midazolam in an oral formulation. *Anesth Prog.* 4: 17-22 (1997).

Delomenie C, Goodfellow GH, Krishnamoorthy R, **Grant DM**, Dupret JM: Study of the role of the highly conserved residues Arg9 and Arg64 in the catalytic function of human N-acetyltransferases NAT1 and NAT2 by site-directed mutagenesis. *Biochem J.* 323: 207-215 (1997).

Gaedigk A, Leeder JS, **Grant DM**: Tissue-specific expression and alternative splicing of human microsomal epoxide hydrolase. *DNA & Cell Biology* 16: 1257-1266 (1997).

Gaedigk A, Beatty BG, **Grant DM**: Cloning, structural organization, and chromosomal mapping of the human phenol sulfotransferase STP2 gene. *Genomics* 40: 242-246 (1997).

Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R: Human acetyltransferase polymorphisms. *Mutation Res.* 376: 61-70 (1997).

Okey AB, Giannone JV, Smart W, Wong JMY, Manchester DK, Parker NB, Feeley MM, **Grant DM**, Gilman A: Binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin to AH receptor in placentas from normal versus abnormal pregnancy outcomes. *Chemosphere* 34: 1335-1347 (1997).

Windmill KF, McKinnon RA, Zhu X, Gaedigk A, **Grant DM**, McManus ME: The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. *Mutation Res.* 376: 153-160 (1997).

Grupp LA, Hsu G, Ng N, Harding S: Glucose and insulin-releasing drug tolbutamide attenuate the effects of morphine and angiotensin on alcohol consumption. *Alcohol* 14: 71-79 (1997).

Grupp LA, Lau V, Harding S: The reduction in alcohol intake by 5-HT_{1A} agonist 8-OHDPAT and its attenuation by the alpha₂ adrenergic antagonist idazoxan correlates with blood glucose levels. *Psychopharmacology* 133: 172-178 (1997).

"H"

Ahmad N, Grad HA, **Haas DA**, Aronson KA, Jokovic A, and Locker D: The efficacy of non-opioid analgesics for post-operative dental pain: a meta-analysis. *Anesthesia Progress* 44: 119-127 (1997).

Nkansah PJ, **Haas DA**, and Saso MA: Mortality incidence in outpatient anesthesia for dentistry in Ontario. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics* 83: 646-651 (1997).

Dorri F, **Hampson DR**, Baskys A, Wojtowicz JM: Down-regulation of mGluR5 by antisense deoxyoligonucleotides alters pharmacological responses to applications of ACPD in the rat hippocampus. *Exper Neurol.* 147: 48-54 (1997).

Thomsen C, Pekhletski R, Halderman B, Gilbert TA, O'Hara PJ, **Hampson DR**: Cloning and characterization of a metabotropic glutamate receptor, mGluR4b. *Neuropharmacology* 36: 21-30 (1997).

Van Dolah FM, Leighfield TA, Haynes BL, **Hampson DR**, Ramsdell JS: A microplate receptor assay for the amnesic shellfish poisoning toxin, domoic acid, utilizing a cloned glutamate receptor. *Analyt Biochem.* 245: 102-105 (1997).

"I"

Fayz S, **Inaba T**: Inhibition of haloperidol carbonyl reduction by non-steroidal anti-inflammatory drugs in human liver cytosol. *Drug Metab Drug Interaction* 13: 301-306 (1997).

Houle S, Wilson AA, **Inaba T**, Fischer N, DaSilva JN: Imaging the 5-HT_{1A} receptors with positron emission tomography: initial humans studies with [¹¹C]CPC-222. *Nucl Med Comm.* 18: 1130-1134 (1997).

Inaba T, Fischer NE, Riddick DS, Stewart DJ, Hidaka T: HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. *Toxicol Lett.* 93: 215-219 (1997).

Wu D, Otton SV, **Inaba T**, Kalow W, Sellers EM: Interactions of amphetamine analogs with human liver CYP2D6. *Biochem Pharmacol.* 53: 1605-1612 (1997).

Bailey B, **Ito S**. Breast-feeding and maternal medication. *Ped Clin North Am.* 44: 41-54 (1997).

Chattergoon DS, McGuigan MA, Koren G, Hwang P, **Ito S**: Multidrug dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valproic acid. *Neurology* 49: 1442-1444 (1997).

Woodland C, Verjee Z, Giesbrecht E., Koren G, **Ito S**: The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. *J Pharmacol Exp Ther.* 283: 39-45 (1997).

"J"

Francis J, Jugloff DGM, Mingo NS, Wallace MC, **Jones OT**, Burnham, WM, Eubanks JH: Kainic acid induced generalized seizures alter the regional hippocampal expression of the rat Kv4.2 potassium channel gene. *Neurosci Lett.* 232: 91-94 (1997).

Jones OT, Bernstein GM, Wong W, Jone EJ, Law MH, Jugloff DM, Mills LR: N-type calcium channels in the developing rat hippocampus: subunit, complex and regional expression. *J Neurosci.* 17: 6152-6164 (1997).

Tymianski M, Sattler R, Bernstein GM, **Jones OT**: Preparation, characterization and utility of a novel antibody for resolving the spatial and temporal dynamics of the calcium chelator BAPTA. *Cell Calcium* 22: 111-120 (1997).

Wang Z, Tymianski M, **Jones OT**, Nedergaard M: Impact of cytoplasmic calcium buffering on the spatial and temporal characteristics of intercellular calcium signals in astrocytes. *J Neurosci.* 17: 7359-7371 (1997).

Wickenden AD, Kaprelian R, Parker TG, **Jones OT**, Backx PH: Regulation of the transient outward potassium current and K⁺ channel gene expression by development and thyroid hormone in rat ventricular myocytes. *J Physiol. (London)* 504: 271-286 (1997).

"K"

Kalant H: Commentary: Supply reduction vs. demand reduction - the uses of history. *Addiction* 92: 689-690 (1997).

Kalant H: Opium revisited: a brief review of its nature, composition, non-medical use and relative risks. *Addiction* 92: 267-277 (1997).

Kalant H: Book review: T. Szasz, "Our rights to drugs - The case for a free market". *Addiction* 92: 1371-1373 (1997).

Kalant H, Corrigall WA, Smart RG: Cannabis: a health prespective and research agenda. Geneva: WHO/PSA, vi + pp.49 (1997).

Kalow W, **Kalant H**: Reply to Stephan Jay Gould. *The New York review of books.* 44: p. 56 (October 9, 1997).

Khanna JM, Lê AD, **Kalant H**, Chau A, Shah G: Effect of lipid solubility on the development of chronic cross-tolerance between ethanol and different alcohols and barbiturates. *Pharmacol Biochem Behav.* 57: 101-110 (1997).

Khanna JM, **Kalant H**, Chau, A. and Shah G: Effect of NMDA antagonists on development of rapid tolerance to various barbiturates. *Alcohol.* 15: 1-10 (1997).

Kalow W: Pharmacogenetics in biological perspective. *Pharmacol Rev.* 49: 369-379 (1997).

Kalow W, Kalant H: Reply to Stephan Jay Gould. *The New York review of books.* 44: p. 56 (October 9, 1997).

Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, **Kalow W**: Paroxetine potentiates CNS side effects of perphenazine: Contribution of cytochrome P450 2D6 inhibition in vivo. *Clin Pharmacol Ther.* 62: 334-347 (1997).

Pastrakuljic A, Tang BK, Roberts EA, **Kalow W**: Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. *Biochem Pharmacol.* 53: 531-538 (1997).

Rady-Pentek P, Tang BK, Müller R, **Kalow W**: Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes. *Eur J Clin Pharmacol*. 52: 147-153 (1997).

Wu D, Otton SV, Inaba T, Kalow W, Sellers EM: Interactions of amphetamine analogs with human liver CYP2D6. *Biochem Pharmacol*. 53: 1605-1612 (1997).

Campisi P, Carmichael FJL, Crawford M, Orrego H, **Khanna, J.M**: Role of adenosine in the ethanol induced potentiation of general anesthetics. *Eur J Pharmacol*. 325: 165-172 (1997).

Khanna JM, Shah G, Chau A: Effect of NMDA antagonists on rapid tolerance to ethanol under two different testing paradigms. *Pharmacol Biochem Behav*. 57: 693-697 (1997).

Khanna JM, Chau A, Shah G: Effect of NMDA antagonists on rapid tolerance to benzodiazepines. *Brain Res Bull*. 42: 99-103 (1997).

Khanna JM, Lê AD, Kalant H, Chau A, Shah G: Effect of lipid solubility on the development of chronic cross-tolerance between ethanol and different alcohols and barbiturates. *Pharmacol Biochem Behav*. 57: 101-110 (1997).

Khanna JM, Kalant H, Chau, A. and Shah G: Effect of NMDA antagonists on development of rapid tolerance to various barbiturates. *Alcohol*. 15: 1-10 (1997).

Guttman M, Burkholder J, **Kish SJ**, Hussey D, Wilson A, January 28, 1999 J, Houle S: [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naïve Parkinson's disease: implications for the symptomatic threshold. *Neurology* 48: 1578-1583 (1997).

Kish SJ, Guttman M, Robitaille Y, el-Awar M, Chang LJ, Levey AI: Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1. *Neurology* 48: 1109-1111 (1997).

Kish SJ: Brain energy metabolizing enzymes in Alzheimer's disease: alpha-ketoglutarate dehydrogenase complex and cytochrome oxidase. *Annals New York Acad Sci*. 826: 218-228 (1997).

Rahman S, Li PP, Young LT, Kofman O, **Kish SJ**, Warsh JJ: Reduced [3H]cAMP binding in postmortem brain from subjects with bipolar affective disorder. *J Neurochem*. 68: 297-304 (1997).

Ross BM, Hudson C, Erlich J, Warsh JJ, **Kish SJ**: Increased phospholipid breakdown in schizophrenia: evidence for involvement of a calcium-independent phospholipase A2. *Arch Gen Psychiat*. 54: 487-494 (1997).

- Bailey B, Klein J, **Koren G**: Noninvasive methods for drug measurement in pediatrics. *Pediatr Clin North Amer.* 44: 15-26 (1997).
- Bailey B, Lee A, Addis A, Lau M, **Koren G**: Cisapride use during human pregnancy; A prospective, controlled multicenter study. *Dig Dis Sci* 42: 1848-1852 (1997).
- Berkovitch M, Livne A, Lushkov G, Barr J, Tauber T, Estel G, **Koren G**, Bistritzer Z: Acute iron intoxication: Significant differences between sexes. *Vet Hum Toxicol.* 39: 265-267 (1997).
- Blowey D, Hebert D, Arbus GS, Pool R, Korus M, **Koren G**: Compliance with cyclosporine in adolescent renal transplant recipients. *Pediatr Nephrol.* 11: 547-551 (1997).
- Chattergoon DS, McGuigan MA, **Koren G**, Hwang P, Ito S: Multidrug dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valproic acid. *Neurology* 49: 1442-1444 (1997).
- Davies HD, King SM, Doyle J, Matlow A, **Koren G**, Hamilton R, Portwine C: Randomized, blinded, and controlled pilot study of rapid amphotericin B infusions in children. *Arch Dis Child* 76: 165-166 (1997).
- Diav-Citrin O, **Koren G**: Oral iron chelation with deferiprone. *Pediatr Clin North Amer* 44: 235-247 (1997).
- Einarson A, Bailey B, Jung G, Spizzirri D, Baillie M, **Koren G**: Prospective controlled study of hydroxyzine and cetirizine in pregnancy. *Ann Allergy Asthma Immunol.* 78: 183-186 (1997).
- Einarson A, Bailey B, Innocencion G, **Koren G**: Accidental electric shock in pregnancy: A prospective cohort study. *Am J Obstet Gynecol.* 176: 678-681 (1997).
- Gladstone J, Levy M, Nulman I, **Koren G**: Characteristics of pregnant women exposed to binge alcohol consumption in Toronto. *Can Med Assoc J.* 156: 789-794 (1997).
- Gorodischer R, Burtin P, Verjee Z, Hwang P, **Koren G**: Is saliva suitable for therapeutic drug monitoring of anticonvulsants in children? An evaluation in the routine clinical setting. *Ther Drug Monit.* 19: 637-642 (1997).
- Kennedy D, Pastuszak A, **Koren G**: Taking folic acid during pregnancy; Don't leave it too late". *Can Fam Physician* 43: 2113-2114 (1997).
- Kopecky EA, Jacobson S, Klein J, **Koren G**: Correlation of morphine sulfate in blood plasma and saliva in pediatric patients. *Ther Drug Monit.* 19: 530-534 (1997).
- Kopecky EA, Jacobson S, Joshi P, Martin M, **Koren G**: Review of a home-based palliative care program for children with malignant and non malignant diseases. *J Palliat Care* 13: 28-33 (1997).
- Koren G**: Outcomes for babies exposed in utero to cocaine. *Imprint* 17: 18-20, 1996/97.
- Koren G**: Children of Neverland. *Can Fam Physician.* 43: 619-621 (1997).

Koren G: Bias against the null hypothesis in maternal-fetal drug therapy. *Clin Pharmacol Ther.* 62: 1-5 (1997).

Koren G: New expectations for the role of clinical pharmacologists and industry in protecting unborn babies and their mothers. *Can J Clin Pharmacol.* 4: 62-63 (1997).

Koren G: Is the fetus safe when spermicides fail? *Can Fam Physician* 43: 431-432 (1997).

Koren G, Klein J: Neonatal hair test for cocaine; Toronto experience. *Can Fam Physician* 43: 1215-1219 (1997).

Koren G: Periconception folic acid supplementation: Knowledge and practice of Canadian family physicians. *Can Fam Physician* 43: 851-852 (1997).

Koren G, Pastuszak A: How to ensure fetal safety when mothers use isotretinoin (Accutane). *Can Fam Physician* 43: 216-219 (1997).

Lalkin A, Magee L, Addis A, Loebstein A, **Koren G:** Acid suppressing drugs during pregnancy. *Can Fam Physician* 43: 1192-1197 (1997).

Liau-Chu M, Theis JGW, **Koren G:** A mechanism of anaphylactoid reactions: Improper preparation of high dose intravenous cyclosporine leads to bolus infusion of chemaphare EL and cyclosporine. *Ann Pharmacother.* 31: 1287-1290 (1997).

Loebstein R, **Koren G:** Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: The Motherisk experience. *J Psychiatr Neurosci.* 22: 192-196 (1997).

Loebstein R, Lalkin A, **Koren G:** Pharmacokinetic changes during pregnancy and their clinical relevance. *Clin Pharmacokinet.* 33: 328-343 (1997).

Loebstein R, Diav-Citrin O, Olivieri N, **Koren G:** Deferiprone-induced agranulocytosis; A critical review of 5 rechallenged cases. *Clin Drug Invest.* 13: 345-349 (1997).

Loebstein R, **Koren G:** The ethics of multiple sampling in children for research. *Ther Drug Monit.* 19: 251 (1997).

Loebstein R, Nulman I, **Koren G:** Fetal alcohol syndrome - An ongoing pediatric challenge. *Paediatr Child Health J.* 2: 102-105 (1997).

Mazzotta P, Magee L, **Koren G:** Therapeutic abortions due to severe morning sickness; Unacceptable combination. *Can Fam Physician* 43: 1055-1057 (1997).

Morris P, Binienda PZ, Gillam MP, Klein J, McMartin K, **Koren G, Duhart HM, Slikker W, Paule MG:** The effect of chronic cocaine exposure throughout pregnancy on maternal and infant outcomes in the rhesus monkey. *Neurotoxicol Teratol.* 19: 47-58 (1997).

Nulman I, Scolnik D, Chitayat D, Farkas LD, **Koren G:** Dysmorphology in children exposed in utero to phenytoin and carbamazepine monotherapy; Independent effects of epilepsy and medications. *Am J Hum Genet.* 68: 18-24 (1997).

- Nulman I, Rovet J, Stewart D, Wolpin J, Gardner HA, Theis JGW, Kulin N, **Koren G**: Neurodevelopment of children exposed in utero to antidepressant drugs. *N Engl J Med*. 336: 258-262 (1997).
- Pastuszak A, Burke B, **Koren G**: When potent teratogens are irreplaceable drugs: Lesions of thalidomide and isotretinoin. *Can J Clin Pharmacol*. 4: 67-73 (1997).
- Pope E, Berkovitch M, Klein J, Fassos F, **Koren G**: Salivary measurement of deferiprone concentrations and correlation with serum levels. *Ther Drug Monit*. 19: 95-97 (1997).
- Rathnapalan S, King S, **Koren G**: Testing women for HIV. *Can Fam Physician* 43: 1349-1351 (1997).
- Rowe C, Verjee Z, **Koren G**: Adolescent dimenhydrinate abuse: Resurgence of an old problem. *J Adolesc Health* 21: 47-49 (1997).
- Rowe C, **Koren G**: Effectiveness of the medication error review process at a tertiary pediatric hospital. *Can J Clin Pharmacol*. 4: 75-78 (1997).
- Seto A, Einarson T, **Koren G**: Pregnancy outcome following first trimester exposure to antihistamines: A meta-analysis. *Am J Perinatal*. 14: 119-124 (1997).
- Shilalukey K, Kaufamn M, Bradley S, Francombe WH, Amankwah K, Goldberg E, Shear N, Olivieri NF, **Koren G**: Counseling sexually active teenagers treated with potential human teratogens *J Adolesc Med*. 21: 143-146 (1997).
- Simone C, Byrne BM, Derewlany LO, **Koren G**: The transfer of cocaethylene across the human term placental cotyledon perfused in vitro. *Reprod Toxicol*. 11: 215-219 (1997).
- Taddio A, Katz J, Ilersch L, **Koren G**: Neonatal circumcision and pain response during routine vaccination 4 to 6 months later. *Lancet* 349: 599-603 (1997).
- Taddio A, Stevens B, Craig K, Rastogi P, BenDavid S, Shennan A, Mulligan P, **Koren G**: The efficacy and safety of lidocaine prilocaine cream for neonatal circumcision pain. *N Engl J Med* 336: 1197-1201 (1997).
- Theis JGW, Selby P, Ikizler Y, **Koren G**: Current management of the neonatal abstinence syndrome; A critical analysis of the evidence. *Biol Neonate* 71: 345-356 (1997).
- Theis JGW, **Koren G**, Daneman R, Sherwin AL, Menzano E, Cortez M, Hwang P: Interactions of clobazam with conventional antiepileptics in children. *J Child Neurol*. 12: 208-213 (1997).
- Ursitti F, Klein J, **Koren G**: Clinical utilization of the neonatal hair test for cocaine; A four year experience in Toronto. *Biol Neonate* 72: 345-351 (1997).
- Woodland C, Verjee Z, Giesbrecht E, **Koren G**, Ito S: The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. *J Pharmacol Exp Ther*. 283: 39-45 (1997).

"L"

Buczek Y, Tomkins DM, **Le AD**, Sellers EM: Opposite effects of Ro 15-4513 on acquisition and maintenance of ethanol drinking behavior in male Wistar rats. *Alcoholism Clin Exper Res.* 21: 1667-1675 (1997).

Khanna JM, **Lê AD**, Kalant H, Chau A, Shah G: Effect of lipid solubility on the development of chronic cross-tolerance between ethanol and different alcohols and barbiturates. *Pharmacol Biochem Behav.* 57: 101-110 (1997).

Le AD, Tomkins D, Higgins G, Quan B, Sellers EM: Effects of 5-HT₃, D1 and D2 receptor antagonists on ethanol- and cocaine-induced locomotion. *Pharmacol Biochem Behavior* 57: 325-332 (1997).

Emamghoreishi M , Schlichter L, **Li PP**, Parikh S, Sen J, Kamble A, Warsh JJ: Elevated intracellular calcium in transformed lymphoblasts from patients with Bipolar I Disorder: a trait marker for a bipolar subtype. *Am J Psychiatry* 154: 976-982 (1997).

Kofman O, **Li PP**, Warsh JJ: Differential effects of lithium and carbamazepine on hyperactivity induced by intra-accumbens cholera toxin. *Pharmacol Biochem Behav.* 59: 1-10 (1997).

Mathews R , **Li PP**, Young LT, Warsh JJ: Increased G q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. *Biol Psychiat.* 41: 649-656 (1997).

Rahman S , **Li PP**, Young LT, Kofman O, Kish SJ, Warsh JJ: Reduced [3H]cAMP binding in postmortem brain from subjects with bipolar affective disorder. *J Neurochem.* 68: 297-304 (1997).

Wang JF, Young LT, **Li PP**, Warsh JJ: Signal Transduction Abnormalities in Bipolar Disorder. In: Young LT, Joffe RT eds. *Bipolar Disorder: Biological Models and their Clinical Application*, New York:Marcel Darker, pp41-79 (1997).

"M"

Jarvis CR, Xiong Z-G, Plant JR, Churchill D, Lu W-Y, MacVicar BA, **MacDonald JF**: Neurotrophin modulation of NMDA receptors in cultured murine and isolated rat neurons. *J Neurophysiol.* 78: 2363-2371 (1997).

MacDonald JF: Phosphorylation targets the functional gating of a glutamate channel. *J Physiol.* 503: 469 (1997).

Orser BA, Pennefather PS, **MacDonald JF**: Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. *Anesthesiology* 86: 903-917 (1997).

Wan Q, Xiong ZG, Man HY, Ackerley CA, Braunton J, Lu WY, Becker LE, **MacDonald JF**, Wang YT: Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. *Nature* 388: 686-690 (1997).

Xiong Z, Lu W, **MacDonald JF**: Extracellular calcium sensed by a novel cation channel in hippocampal neurons. *Proc Natl Acad Sci. USA* 94: 7012-7017 (1997).

MacLeod SM: Change and the academic health science centre: a 1997 perspective. *Clin Investig Med.* 20: 399-404 (1997).

MacLeod SM: Report on ACMC annual meeting. Summary of proceedings: the first set report to plenary session, May 5, 1997. *Clin Investig Med.* 20: 422-427 (1997).

MacLeod SM: Report of ACMC annual meeting. Summary of proceedings: the second set report to plenary session, May 6, 1997. *Clin Investig Med.* 20: 428-432 (1997).

Holbrook AM, **MacLeod SM**, Fisher P, Levine MA: Developing a Canadian prescribing practices network. Network Development Committee of the Canadian Prescribing Practices Network Project. *CMAJ.* 154: 1325-1331 (1996).

MacLeod SM: Improving physician prescribing practices: bridge over troubled waters [editorial]. *CMAJ.* 154: 675-677 (1996).

MacLeod SM: Research in medical schools: rationale, priorities, roles and balance. *Clin Investig Med.* 19: 204-213 (1996).

Baker B, Dorian P, Sandor P, Shapiro C, Schell C, **Mitchell J**, Irvine MJ: Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. *J Clin Psychopharmacol.* 17: 15-21 (1997).

Mitchell J, Bansal A: Dexamethasone increases Gq-11 expression and hormone-stimulated phospholipase C activity in UMR-106-01 cells. *Am J Physiol.* 273:E528-E535 (1997).

Mittmann N, Herrmann N, Einarson TR, Busto UE, Lanctot KL, Liu BA, Shulman KI, Silver IL, Naranjo CA, Shear NH: The efficacy, safety and tolerability of antidepressants in late life depression: A meta-analysis. *J Affective Disorders* 46: 191-217 (1997).

Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, Shear NH: Montgomery Asberg severity predictors. *Am J Psychiatry* 154: 1320-1321 (1997).

Mittmann N, Herrmann N, Einarson TR, Busto UE, Lanctot KL, Liu BA, Shulman KI, Silver IL, Naranjo CA, Shear NH: The efficacy, safety and tolerability of antidepressants in late life depression: A meta-analysis. *J Affective Disorders* 46: 191-217 (1997).

Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, Shear NH: Montgomery Asberg severity predictors. *Am J Psychiat.* 154: 1320-1321 (1997).

"N"

Herrmann N, Bremner KE, **Naranjo CA**: Pharmacotherapy of late life mood disorders. *J Clin Neurosci.* 4: 41-47 (1997).

Naranjo CA, Herrmann N, Lanctot KL, Best TS: Pharmacotherapeutic management of behavioural disorders in dementia. *Int Psychiatry Today* 7: 1-6 (1997).

Naranjo CA, Shulman RW, Ozdemir V: Development and evaluation of a clinical psychopharmacology educational curriculum. *J Clin Pharmacol.* 37: 474-479 (1997).

Naranjo CA, Dongier M, Bremner KE: Long-acting injectable bromocriptine does not reduce relapse in alcoholics. *Addiction* 92: 969-978 (1997).

Naranjo CA, Bremner KE, Bazoon M, Turksen IB. Using fuzzy logic to predict response to citalopram in alcohol dependence. *Clin Pharmacol Ther* 62: 209-224 (1997).

Ozdemir V, **Naranjo CA**, Herrmann N, Reed K, Sellers EM, Kalow W: Paroxetine potentiates CNS side effects of perphenazine: Contribution of cytochrome P450 2D6 inhibition in vivo. *Clin Pharmacol Ther.* 62: 334-347 (1997).

Sproule BA, Bazoon M, Shulman KI, Turksen IB, **Naranjo CA**: Fuzzy logic pharmacokinetic modelling: Application to lithium concentration prediction. *Clin Pharmacol Ther.* 62: 29-40 (1997).

Sproule B, **Naranjo CA**, Bremner KE, Hassan P: Selective serotonin reuptake inhibitors and CNS drug interactions. *Clin Pharmacokin.*

Cameron RG, **Neuman MG**, Shear NH, Blendis LM: Multivesicular stellate cells in primary biliary cirrhosis. *Hepatology* 26: 819-822 (1997).

Cardinaud B, Gilbert JM, Sugamori KS, Vincent JD, **Niznik, HB**, Vernier P: Comparative aspects of dopaminergic neurotransmission in vertebrates. In: Vaudry H, Roubos EW, de Loof A, eds. *Comparative Endocrinology and Neurobiology: From Molecular to Integrative Biology.* *Annals New York Acad Sci.* 839:47-52. (1997).

Cardinaud B, Sugamori KS, Coudouel S, Vincent JD, **Niznik HB**, Vernier P: Early emergence of three dopamine D1 receptor subtypes in vertebrates: Molecular phylogenetic, pharmacological

and functional criteria defining D1A, D1B and D1C receptors in European eel *Anguilla anguilla*. *J Biol Chem.* 272: 2778-2787 (1997).

Cardinaud B, Gilbert JM, Liu F, Sugamori KS, Vincent JD, **Niznik HB**, Vernier P: Evolution and origin of the diversity of dopamine receptors in vertebrates. In: Goldstein D, Eisenhofer G, McCarty R, eds. Catecholamines: Bridging Basic Science with Clinical Medicine. *Advances in Pharmacology* Vol.42, Academic Press, pp936- 940 (1997).

Lee FJS, Pristupa ZB, Ciliax BJ, Levey AI, **Niznik HB**: The dopamine transporter carboxyl terminus: Truncation/substitution mutants confer high affinity dopamine uptake while attenuating recognition of the ligand binding domain. *J Biol Chem.* 271: 20885-20894 (1997).

Madras BK, Pristupa ZB, **Niznik HB**, Liang AY, Blundell P, Gonzalez MD, Meltzer PC: Nitrogen based drugs are not essential for blockade of monoamine transporters. *Synapse* 24: 340-348 (1997).

Nair V, **Niznik HB**, Mishra RK: NMDA and dopamine D2L receptor interaction in human neuroblastoma SH-SY5Y cells involves tyrosine kinase and phosphatase. *NeuroReport* 7: 2937-2940 (1997).

Niznik HB, Liu F, Sugamori KS, Cardinaud B, Vernier P: Expansion of the dopamine D1 receptor gene family: Defining molecular, pharmacological and functional criteria for D1A, D1B, D1C and D1D receptors. In: Goldstein D et al, eds. Catecholamines: Bridging Basic Science with Clinical Medicine. *Adv Pharmacol* Vol.42, Academic Press, pp404-408 (1997).

Pristupa ZB, Sunahara RK, **Niznik HB**: G protein α and β subunits as possible mediators of dopamine D1: D2 receptor ligand binding interactions. In: Mishra RK, Baker GB, Boulton AA eds. Role of G-proteins in Psychiatric and Neurological Disorders. *Neuromethods* : Vol. 31: *G-Protein Methods and Protocols*. Humana Press, pp 81-118 (1997).

Rajakumar N, Laurier L, **Niznik HB**: Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine induced behaviors in the rat. *Synapse* 26: 199-208 (1997).

Nobrega, J.N.

Nobrega JN, Richter A, Jiwa D, Raymond R, Loscher W: Alterations in N-methyl-d-aspartate receptor binding in dystonic hamster brains. *Brain Res.* 744: 161-165 (1997).

Nobrega JN, Raymond R, Puymirat J, Belej T, Joffe RT: Regional changes in β_1 thyroid hormone receptor immunoreactivity in rat brain after thyroidectomy. *Brain Res.* 761: 161-164 (1997).

Sasaki T, Kennedy J, **Nobrega JN**: Localized changes in the GABA-gated chloride channel in rat brain after long-term haloperidol: relation to vacuous chewing movements. *Synapse* 25: 73-79 (1997).

Seeman P, Guan, H-C, **Nobrega J**, Jiwa D, Markstein R, Balk J-H, Picetti R, Borelli E, Van Tol HHM: Dopamine D2-like sites in schizophrenia, but not in Huntington's, Alzheimer's or control brains, for [3H]benzquinoline. *Synapse* 25: 137-146 (1997).

"O"

Jin H, Zastawny R, George SR, **O'Dowd BF**: Elimination of palmitoylation sites in the human D1 dopamine receptor by site-directed mutagenesis does not affect receptor-G protein coupling. *Eur J Pharmacol.* 324: 109-116 (1997).

Jung BP, Nguyen T, Kolakowski LF jr., Lynch KR, Heng HQ, George SR, **O'Dowd BF**: Discovery of a novel human G protein-coupled receptor gene (GPR25) located on chromosome. *Biochem Biophys Res Comm.* 230: 69-72 (1997).

Ng GYK, Varghese G, Chung HC, Trogadis J, Seeman P, **O'Dowd BF**, George SR: Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells. *Endocrinology* 138: 4199-4205 (1997).

Ng GYK, George SR, **O'Dowd BF**: Studies on Dopamine Receptors and Role in Drug Addiction. In: *Handbook of Psychiatric Genetics*. CRC Press, Inc, pp. 89-105 (1997).

O'Dowd BF, Nguyen T, Lynch K, Kolakowski F, Thompson M, Cheng R, Marchese A, Ng G, Heng HHQ, George SR: A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain. *FEBS Letters* 394: 325-329 (1997).

O'Dowd BF, Nguyen T, Jung B, Marchese A, Cheng R, Heng HHQ, Kolakowski LF, Lynch K, George SR: Cloning and chromosomal mapping of four novel human G protein-coupled receptor genes. *Gene* 187: 75-81 (1997).

Pak Y, **O'Dowd BF**, George SR: Agonist-induced desensitization of the mu opioid receptor is determined by 394Thr preceded by acidic amino acids in the COOH terminal tail. *J Biol Chem.* 272: 24961-24965 (1997).

Sawzdargo M, George SR, Nguyen T, Xu S, Kolakowski LF, **O'Dowd BF**: A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to the CD22 gene on chromosome 19q13.1. *Biochem Biophys Res Comm.* 239: 543-547 (1997).

Zastawny RL, George SR, Bouvier M, **O'Dowd BF**: Structure of the Adrenergic and Related Receptors. In: *Encyclopedia of Human Biology*, Second Edition, Vol. 1, Academic Press. pp145-156 (1997).

Okey, A.B.

Okey AB, Giannone JV, Smart W, Wong JMY, Manchester DK, Parker NB, Feeley MM, Grant DL, Gilman A: Binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin to AH receptor in placentas from normal versus abnormal pregnancy outcomes. *Chemosphere* 34: 1335-1347 (1997).

"P,Q"

Demin PM, Kochev DM, Perrier H, **Pace-Asciak CR**, Pivnitsky KK: Synthesis of a photoaffinic hepoxilin analog. *Mendeleev Comm.* 1-2 (1997).

Mills L, Reynaud D, **Pace-Asciak CR**: Hepoxilin-evoked intracellular reorganization of calcium in human neutrophils: a confocal microscopy study. *Exper Cell Res.* 230: 337-341 (1997).

Reynaud D, **Pace-Asciak CR**: Docosahexaenoic acid causes the accumulation of free arachidonic acid in rat pineal gland and hippocampus to form hepoxilins from both substrates. *Biochim Biophys Acta* 1346: 305-316 (1997).

Reynaud D, Rounova O, Demin PM, Pivnitsky KK, **Pace-Asciak CR**: Hepoxilin A3 is oxidized by human neutrophils into its w-hydroxy metabolite by an activity independent of LTB4 omega hydroxylase. *Biochim Biophys Acta*, 1348: 287-298 (1997).

Chen J, **Pang KS**: Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone conjugation in the serially perfused rat intestine and liver preparations. *J Pharmacol Exp Ther.* 280: 24-31 (1997).

Doherty MM, **Pang KS**: First-pass effect: significance of the intestine for absorption and metabolism. *Drug Chem Toxicol.* 20: 329-344 (1997).

Ouwerkerk-Mahadevan S, Tirona RG, Ripping RA, Ploemen JH, van Bladeren PJ, **Pang KS**, van Boom JH, Mulder GJ: Inhibition of GSH conjugation by GSH analogues in the perfused rat liver. Effect of esterification on the potency of gamma-L-glutamyl-alpha-(D-2-aminoadipyl)-N-2-heptylamine. *Drug Metab Dispos.* 25:1137-1143 (1997).

Orser BA, **Pennefather PS**, MacDonald JF: Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. *Anesthesiology* 86: 903-917 (1997).

"R"

Safa B, Lee C, **Riddick DS**: Role of the aromatic hydrocarbon receptor in the suppression of cytochrome P-450 2C11 by polycyclic aromatic hydrocarbons. *Toxicol Lett.* 90: 163-175 (1997).

Gilmour SM, Hershkop M, Reifen R, Gilday D, **Roberts EA**: Outcome of hepatobiliary scanning in neonatal hepatitis syndrome. *J. Nuclear Med.* 38: 1279-1282 (1997).

Kono Y, Yang S, **Roberts EA**: Extended primary culture of human hepatocytes in a collagen gel sandwich system. *In Vitro Cellular Developm Biol Animal.* 33: 467-472 (1997).

Pastrakuljic A, Tang BK, **Roberts EA**, Kalow W.: Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. *Biochem Pharmacol.* 53: 531-538 (1997).

Zu Putlitz J, **Roberts EA**, Wieland S, Kono Y, Blum HE: Hepatitis B virus replication and viral antigen synthesis in hepatocyte lines derived from normal human liver. *Virus Res.* 52: 177-182 (1997).

Rozmahel R, Gyosomsrey K, Plyte S, Wilschanski M, Durie P, Be CE, Tsui L-C: Incomplete rescue of cystic fibrosis transmembrane conductance regulator deficient mice by the human CFTR. *Human Mol Genet.* 6: 1153-1162 (1997).

Rozmahel R, Heng HQ, Duncan A, Shi XM, Rommens JM, Tsui L-C: Amplification of CFTR exon 9 sequences to multiple locations in the human genome. *Genomics* 45: 554-561 (1997).

"S"

Lotfi CFP, Todorovic Z, Armelin HA, **Schimmer BP**: Unmasking a growth-promoting effect of the adrenocorticotrophic hormone in Y1 mouse adrenocortical tumor cells. *J Biol Chem.* 272: 29886-29891 (1997).

Parker KL, **Schimmer BP**: Steroidogenic factor 1: A key determinant of endocrine development and function. *Endocrine Rev.* 18: 361-377 (1997).

Wong M, Ikeda Y, Luo X, Caron KM, Weber TJ, Swain A, **Schimmer BP**, Parker KL: Steroidogenic factor 1 plays multiple roles in endocrine development and function. *Rec Prog Hormone Res.* 52: 167-184 (1997).

Seeman P: Clozapine withdrawal: serotonergic or dopaminergic mechanisms? *Arch Gen Psychiat.* 54: 762-763 (1997).

Seeman P: Neurobiology of dopamine receptors, antipsychotic drugs and schizophrenia. *Biol Psychiat.* 42: 198S-199S (1997).

Seeman P, Corbett R, Van Tol HHM: Dopamine D4 receptors may alleviate antipsychotic-induced Parkinsonism. In: Goldstein DS, Eisenhofer G, McCarty R, eds. Catecholamines. *Adv Pharmacol.* 42: 478-482. San Diego: Academic Press (1997).

Seeman P, Corbett R, Van Tol HHM: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4. *Neuropsychopharmacology* 16: 93-110 and 16: 127-135 (1997).

Seeman P, Guan, H-C, Nobrega J, Jiwa D, Markstein R, Balk J-H, Picetti R, Borelli E, Van Tol HHM: Dopamine D2-like sites in schizophrenia, but not in Huntington's, Alzheimer's or control brains, for [3H]benzquinoline. *Synapse* 25: 137-146 (1997).

Seeman P, Kapur S: Clozapine occupies high levels of dopamine D2 receptors. *Life Sci.* 60: 207-216 (1997).

Seeman P, Tallerico T, Corbett R, Van Tol HHM: Commentary: Role of dopamine D2, D4, and serotonin 2A receptors in antipsychotic action and anticataleptic action. *J Psychopharmacol.* 11: 17-19 (1997).

Buczek Y, Tomkins DM, Le AD, **Sellers EM:** Opposite effects of Ro 15-4513 on acquisition and maintenance of ethanol drinking behavior in male Wistar rats. *Alcoholism Clin Exper Res.* 21: 1667-1675 (1997).

Cheung SW, Nolte H, Otton SV, Tyndale RF, Wu PH, **Sellers EM:** Simultaneous determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. *J Chromatography B: Biomed Appl* 690: 77-87 (1997).

Kaplan HL, Busto UE, Baylon GJ, Cheung SW, Otton SV, Somer G, **Sellers EM:** Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. *J Pharmacol Exp Ther.* 281: 103-108 (1997).

Le AD, Tomkins D, Higgins G, Quan B, **Sellers EM:** Effects of 5-HT₃, D1 and D2 receptor antagonists on ethanol- and cocaine-induced locomotion. *Pharmacol Biochem Beh.* 57: 325-332 (1997).

Messina ES, Tyndale RF, **Sellers EM:** A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. *J Pharmacol Exp Ther.* 282: 1608-1614 (1997).

Nowak MP, Tyndale RF, **Sellers EM:** CYP2D6 phenotype and genotype in a Canadian Native Indian population. *Pharmacogenetics* 7: 145-148 (1997).

Ozdemir V, Naranjo CA, Herrmann N, Reed K, **Sellers EM**, Kalow W: Paroxetine potentiates CNS side effects of perphenazine: Contribution of cytochrome P450 2D6 inhibition in vivo. *Clin Pharmacol Ther.* 62: 334-347 (1997).

Sellers EM, Otton SV, Tyndale RF: The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse. *NIDA Res Monograph* 173: 6-26 (1997).

Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, Tyndale RF, **Sellers EM**: Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. *J Pharmacol Exp Ther.* 280: 1374-1382 (1997).

Tyndale RF, Droll KP, **Sellers EM**: Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. *Pharmacogenetics* 7: 375-379 (1997).

Tyndale RF, **Sellers EM**: P450 in opiate addiction: A deficient phenotype? In: Nahas GG, Burks TF, eds. *Drug Abuse in the Decade of the Brain*. Amsterdam: IOS Press, pp79-87 (1997).

Wu D, Otton SV, Inaba T, Kalow W, **Sellers EM**: Interactions of amphetamine analogs with human liver CYP2D6. *Biochem Pharmacol.* 53: 1605-1612 (1997).

Kuhne T, **Semple JW**, Butchart S, Freedman J, Blanchette VS: Platelet and immune response to oral high-dose dexamethasone in childhood chronic immune thrombocytopenic purpura. *J Pediatrics* 130: 17-24 (1997).

Lazarus AH, Crow AR, **Semple, JW**, Cosgrave D, Kalovski EJ, Hannach, Blanchette V, Freedman J: Induction of a secondary human anti-HLA alloimmune response in severe combined immunodeficient mice engrafted with human lymphocytes. 37: 1192-1199 (1997).

Semple JW, Siminovitch KA, Mody M, Milev Y, Lazarus AH, Wright JF and J Freedman. Flow cytometric analysis of platelets from children with the wiskott-aldrich syndrome (WAS): defects are consistent with a cytoskeletal abnormality. *Brit J Haematology* 97: 747-754 (1997).

Semple JW, Cosgrave D, Speck ER, Bang A, Blanchette VS, Freedman J: Recipient immune responses induced by allogeneic whole blood or platelet transfusions: implications for immunomodulation. In: Smit Sibinga C Th, Das PC, The TH, eds. *Cytokines and Growth Factors in Blood Transfusion*. Kluwer Acad Publ, Dordrecht, NL. pp 29-45 (1997).

Cameron RG, Neuman MG, Shear NH, Blendis LM: Multivesicular stellate cells in primary biliary cirrhosis. *Hepatology* 26: 819-822 (1997).

Drake LA, **Shear NH**, Arlette JP, et al.: Oral terbinafine in the treatment of toenail onychomycosis: North American Multicenter trial. *J Am Acad Dermatol.* 37: 740-745 (1997).

Einarson TR, **Shear NH**, Oh PI: Models for pharmacoeconomic analysis. *Can J Clin Pharmacol.* 4: 25-29 (1997).

Gupta AK, **Shear NH**: Terbinafine: An update. *J Am Acad Dermatol.* 37: 978-988 (1997).

Gupta AK, **Shear NH**: Onychomycosis: Going for cure. *Can Fam Physician* 43: 299-305 (1997).

Gupta AK, Sibbald RG, Lynde CW, Hull PR, Prussick R, **Shear NH**, DeDoncker P, Elewski BE: Onychomycosis in children: Prevalence and treatment strategies. *J Am Acad Dermatol.* 36: 395-402 (1997).

Knowles S, Shapiro L, **Shear NH**: Serious dermatologic reactions in children. *Curr Opinions Pediatrics* 9: 388-395 (1997).

Liu BA, Gordon M, Labrache JM, Murray TM, Vieth R, **Shear NH**: Seasonal prevalence of vitamin D deficiency in institutionalized older adults. *J Am Geriatr Soc.* 45: 598-603 (1997).

Mittmann N, Herrmann N, Einarson TR, Busto UE, Lanctot KL, Liu BA, Shulman KI, Silver IL, Naranjo CA, **Shear NH**: The efficacy, safety and tolerability of antidepressants in late life depression: A meta-analysis. *J Affective Disorders* 46: 191-217 (1997).

Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, **Shear NH**: Montgomery Asberg severity predictors. *Am J Psychiatry* 154: 1320-1321 (1997).

Oh PI, Gupta AK, Einarson TR, Macrov P, **Shear NH**: Calcipotriol in the treatment of psoriasis of limited severity: Pharmacoeconomic evaluation. *J Cut Med Surg.* 2: 7-15 (1997).

Pon K, **Shear NH**: Bazex syndrome (acrokeratosis paraneoplastica). *J Cut Med Surg.* 2: 86-89 (1997).

Schlienger R, **Shear NH**: Serotoninsyndrom: Eine potentiell schwerwiegende Nebenwirkung unter selektive Serotonin-Wiederaufnahme-Hemmern. *Dtsch med Wschr.* 122: 1495-1499 (1997).

Shapiro LE, Singer MI, **Shear NH**: Pharmacokinetic mechanisms of drug-drug and drug-food interactions in dermatology. *Curr Opinions Dermatol.* 4: 25-31 (1997).

Shapiro LE, Knowles SR, **Shear NH**: Fluoxetine-induced serum sickness-like reaction. *Ann Pharmacother.* 31: 927 (1997).

Shapiro LE, Knowles SR, **Shear NH**: Comparative safety of tetracycline, minocycline, and doxycycline. *Arch Dermatol.* 133: 1224-1230 (1997).

Shear NH: Terfenadine: Where do we stand? *Can J Clin Pharmacol.* 4: 39-41 (1997).

Shilalukey K, Kaufmann M, Bradley S, Francombe WH, Amankwah K, Goldberg E, **Shear N**, Olivieri NF, Koren G: Counseling sexually active teenagers treated with potential human teratogens. *J Adolesc Med.* 21: 143-146 (1997).

Singer M, Shapiro LE, **Shear NH**: Cytochrome P450 3A: Interactions with dermatologic therapies. *J Am Acad Dermatol.* 37: 765-771 (1997).

Singer MI, Sauder DN, **Shear NH**: Informed patient decision making: Cytosporine and skin disease. *J Cut Med Surg*. 1: 203-208 (1997).

Virani A, Mailis A, Shapiro LE, **Shear NH**: Drug interactions in human neuropathic pain pharmacotherapy. *Pain* 73: 3-13 (1997).

"T"

Pastrakuljic A, **Tang BK**, Roberts EA, Kalow W.: Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. *Biochem Pharmacol* . 53: 531-538 (1997).

Rady-Pentek P, **Tang BK**, Müller R, Kalow W.: Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes. *Eur J Clin Pharmacol*. 52: 147-153 (1997).

Buczek Y, **Tomkins DM**, Le AD, Sellers EM: Opposite effects of Ro 15-4513 on acquisition and maintenance of ethanol drinking behavior in male Wistar rats. *Alcoholism Clin Exper Res*. 21: 1667-1675 (1997).

Le AD, **Tomkins D**, Higgins G, Quan B, Sellers EM: Effects of 5-HT₃, D₁ and D₂ receptor antagonists on ethanol- and cocaine-induced locomotion. *Pharmacol Biochem Behavior* 57: 325-332 (1997).

Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, Tyndale RF, Sellers EM: Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. *J Pharmacol Exp Ther*. 280: 1374-1382 (1997).

Cheung SW, Nolte H, Otton SV, **Tyndale RF**, Wu PH, Sellers EM: Simultaneous determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. *J Chromatography B: Biomed Appl* 690: 77-87 (1997).

Messina ES, **Tyndale RF**, Sellers EM: A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. *J Pharmacol Exp Ther*. 282: 1608-1614 (1997).

Nowak MP, **Tyndale RF**, Sellers EM: CYP2D6 phenotype and genotype in a Canadian Native Indian population. *Pharmacogenetics* 7: 145-148 (1997).

Sellers EM, Otton SV, **Tyndale RF**: The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse. *NIDA Res Monograph* 173: 6-26 (1997).

Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, **Tyndale RF**, Sellers EM: Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. *J Pharmacol Exp Ther.* 280: 1374-1382 (1997).

Tyndale RF, Droll KP, Sellers EM: Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. *Pharmacogenetics* 7: 375-379 (1997).

Tyndale RF, Bhawe SV, Hoffmann E, Hoffman PL, Tabakoff B, Tobin AJ, Olsen RW: Pentobarbital decreases the GABA_A receptor gamma 2 long/short mRNA ratio by a mechanism distinct from receptor occupation. *J Pharmacol Exp Ther.* 283: 350-357 (1997).

Tyndale RF, Sellers EM: P450 in opiate addiction: A deficient phenotype? In: Nahas GG, Burks TF, eds. *Drug Abuse in the Decade of the Brain*. Amsterdam:IOS Press, pp79-87 (1997).

"U"

Miyamoto G, Zahid N, **Utrecht JP**: Oxidation of diclofenac to reactive metabolites by neutrophils, myeloperoxidase and hypochlorous acid. *Chem Res Tox.* 10: 414-419 (1997).

Utrecht J, Zahid N, Tehim A, Fu JM, Rakhit S: Structural features associated with reactive metabolite formation in clozapine analogues. *Chemico-Biol Interact.* 104: 117-129 (1997).

Utrecht JP: Current trends in drug-induced autoimmunity. *Toxicology* 119: 37-43 (1997).

Walmsley SL, Winn LM, Harrison ML, **Utrecht JP**, Wells PG: Increased oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. *AIDS* 11: 1689-1697 (1997).

"V"

Sanyal S, **Van Tol HH**: Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. *J Psychiatric Res.* 31: 219-32 (1997).

Sanyal S, **Van Tol HH**: Dopamine D4 receptor-mediated inhibition of cyclic adenosine 3',5'-monophosphate production does not affect prolactin regulation. *Endocrinology* 138: 1871-1878 (1997)

Seeman P, Corbett R, **Van Tol HHM**: Dopamine D4 receptors may alleviate antipsychotic-induced Parkinsonism. In: Goldstein DS, Eisenhofer G, McCarty R, eds. *Catecholamines*. Adv Pharmacol. 42: 478-482. San Diego: Academic Press (1997).

Seeman P, Corbett R, **Van Tol HHM**: Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4. *Neuropsychopharmacology* 16: 93-110 and 16: 127-135 (1997).

Seeman P, Guan, H-C, Nobrega J, Jiwa D, Markstein R, Balk J-H, Picetti R, Borelli E, **Van Tol HHM**: Dopamine D2-like sites in schizophrenia, but not in Huntington's, Alzheimer's or control brains, for [3H]benzquinoline. *Synapse* 25: 137-146 (1997).

Seeman P, Tallerico T, Corbett R, **Van Tol HHM**: Commentary: Role of dopamine D2, D4, and serotonin 2A receptors in antipsychotic action and anticataleptic action. *J Psychopharmacol.* 11: 17-19 (1997).

"W,X,Y,Z"

Kofman O, Li PP, **Warsh JJ**: Differential effects of lithium and carbamazepine on hyperactivity induced by intra-accumbens cholera toxin. *Pharmacol Biochem Behav.* 59: 1-10 (1997).

Mathews R , Li PP, Young LT, **Warsh JJ**: Increased G q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. *Biol Psychiatry* 41: 649-656 (1997).

Rahman S , Li PP, Young LT, Kofman O, Kish SJ, **Warsh JJ**: Reduced [3H]cAMP binding in postmortem brain from subjects with bipolar affective disorder. *J Neurochem.* 68: 297-304 (1997).

Ross BM, Hudson C, Erlich J, **Warsh JJ**, Kish SJ: Increased phospholipid breakdown in schizophrenia: evidence for involvement of a calcium-independent phospholipase A2. *Arch Gen Psychiat.* 54: 487-494 (1997).

Wang JF, Young LT, Li PP, **Warsh JJ**: Signal Transduction Abnormalities in Bipolar Disorder. In: Young LT, Joffe RT eds. *Bipolar Disorder: Biological Models and their Clinical Application*, New York:Marcel Darker, pp 41-79 (1997).

Kim PM, Winn LM, Parman T, **Wells PG**: UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite HPPH. *J Pharmacol Exp Ther.* 280: 200-209 (1997).

Kim PM, DeBoni U, **Wells PG**: Peroxidase-dependent bioactivation and oxidation of DNA and protein in benzo[a]pyrene-initiated micronucleus formation. *Free Rad Biol Med.* 23: 579-596 (1997).

Walmsley SL, Winn LM, Harrison ML, Uetrecht JP, **Wells PG**: Increased oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. *AIDS* 11: 1689-1697 (1997).

Wells PG, Kim PM, Nicol CJ, Parman T, Winn LM: Chapter 17. Reactive intermediates. In: Kavlock RJ, Daston GP, eds. *Handbook of Experimental Pharmacology*, Vol. 124, Part I: Drug Toxicity in Embryonic Development, Heidelberg:Springer-Verlag, pp453-518 (1997).

Wells PG, Kim PM, Laposa RR, Nicol CJ, Parman T, Winn LM: Oxidative damage and teratogenesis. *Mutation Res.* 366: 65-78 (1997).

Wells PG, Winn LM: The role of biotransformation in developmental toxicity. In: Comprehensive Toxicology, vol. 10, Reproductive and Endocrine Toxicology, Sect 3, Harris C, ed. *Developmental Toxicology*, Pergamon Elsevier Sci, pp.489-507 (1997).

Winn LM, **Wells PG**: Evidence for embryonic prostaglandin H synthase-catalysed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis. *Free Rad Biol Med.* 22: 607-621 (1997).